|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 401/12 | (2006.01) |
| A61K 31/506 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3121171 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16167355.3 |
| Date of filing the European patent application | 2011-12-15 | |
| (97) | Date of publication of the European application | 2017-01-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-08-15 |
| (46) | Date of publication of the claims translation | 2018-11-12 |
| (30) | Number | Date | Country code |
| 201061424194 P | 2010-12-17 | US |
| (72) |
FENG, Lili, US
GONG, Baoqing, US
KARPINSKI, Piotr H., US
WAYKOLE, Liladhar Murlidhar, US
|
| (73) |
NOVARTIS AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kristalinės 5-chlor-N2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-N4[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamino formos |
| CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE |
| Payment date | Validity (years) | Amount | |
| 2021-11-29 | 11 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-12-15 |